

Natasha Szuber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7898822/publications.pdf>

Version: 2024-02-01

48
papers

1,107
citations

706676

14
h-index

466096

32
g-index

48
all docs

48
docs citations

48
times ranked

1735
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management. American Journal of Hematology, 2022, 97, 491-505.	2.0	10
2	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases. Blood Cancer Journal, 2022, 12, 44.	2.8	9
3	1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events. Blood Advances, 2022, 6, 3835-3839.	2.5	4
4	Myeloproliferative neoplasms – a global view. British Journal of Haematology, 2022, , .	1.2	3
5	Young platelet millionaires with essential thrombocythemia. American Journal of Hematology, 2021, 96, E93-E95.	2.0	11
6	Risk of infection in <sc>MPN</sc> patients in the era of <sc>C</sc>ovidâ€‹<sc>19</sc>: A prospective multicenter study of <sc>257</sc> patients from the <sc>CMLâ€‹MPN Q</sc>uebec <sc>R</sc>esearch <sc>G</sc>roup. American Journal of Hematology, 2021, 96, E200-E203.	2.0	2
7	Extreme thrombocytosis in lowâ€‹risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. American Journal of Hematology, 2021, 96, E182-E184.	2.0	11
8	Mutations and thrombosis in essential thrombocythemia. Blood Cancer Journal, 2021, 11, 77.	2.8	26
9	Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera. Blood Cancer Journal, 2021, 11, 75.	2.8	16
10	JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. Leukemia, 2021, 35, 2166-2181.	3.3	35
11	Venetoclax with azacitidine or decitabine in blastâ€‹phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American Journal of Hematology, 2021, 96, 781-789.	2.0	46
12	Current Management of Chronic Neutrophilic Leukemia. Current Treatment Options in Oncology, 2021, 22, 59.	1.3	3
13	A populationâ€‹based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. American Journal of Hematology, 2021, 96, E464-E468.	2.0	9
14	<i>JAK2</i> wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. Blood, 2021, 138, 2886-2889.	0.6	12
15	Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases. Blood, 2021, 138, 3629-3629.	0.6	0
16	A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count. Blood, 2021, 138, 238-238.	0.6	2
17	Patterns of Care and Outcomes in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Multicenter Population-Based Study. Blood, 2021, 138, 3650-3650.	0.6	0
18	The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events. Blood, 2021, 138, 3630-3630.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management. American Journal of Hematology, 2020, 95, 212-224.	2.0	27
20	A population-based study of chronic neutrophilic leukemia in the United States. Blood Cancer Journal, 2020, 10, 68.	2.8	8
21	Mutation-enhanced international prognostic systems for essential thrombocythemia and polycythaemia vera. British Journal of Haematology, 2020, 189, 291-302.	1.2	134
22	Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis. Blood, 2020, 136, 4-7.	0.6	2
23	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610.	1.4	103
24	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. Leukemia, 2019, 33, 780-785.	3.3	4
25	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. American Journal of Hematology, 2019, 94, 5-9.	2.0	7
26	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E164-E167.	2.0	1
27	Chronic neutrophilic leukemia: new science and new diagnostic criteria. Blood Cancer Journal, 2018, 8, 19.	2.8	24
28	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. American Journal of Hematology, 2018, 93, 691-697.	2.0	50
29	Driver mutations in primary myelofibrosis and their implications. Current Opinion in Hematology, 2018, 25, 129-135.	1.2	15
30	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. American Journal of Hematology, 2018, 93, 348-355.	2.0	94
31	Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases. American Journal of Hematology, 2018, 93, E61-E64.	2.0	31
32	MPL-mutated essential thrombocythemia: a morphologic reappraisal. Blood Cancer Journal, 2018, 8, 121.	2.8	17
33	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. Blood Cancer Journal, 2018, 8, 118.	2.8	7
34	Genetic predictors of response to specific drugs in primary myelofibrosis. Blood Cancer Journal, 2018, 8, 120.	2.8	1
35	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. American Journal of Hematology, 2018, 93, 1474-1484.	2.0	56
36	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. Blood Cancer Journal, 2018, 8, 21.	2.8	26

#	ARTICLE	IF	CITATIONS
37	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Blood</i> , 2018, 132, 3035-3035.	0.6	1
38	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. <i>Blood</i> , 2018, 132, 3040-3040.	0.6	1
39	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. <i>Blood</i> , 2018, 132, 4300-4300.	0.6	0
40	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. <i>Blood</i> , 2018, 132, 3034-3034.	0.6	0
41	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. <i>Blood</i> , 2018, 132, 1761-1761.	0.6	4
42	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronically after the FDA Approval Date of Anagrelide. <i>Blood</i> , 2018, 132, 4287-4287.	0.6	0
43	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. <i>Blood</i> , 2018, 132, 1767-1767.	0.6	0
44	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. <i>Blood</i> , 2018, 132, 3033-3033.	0.6	0
45	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. <i>Blood</i> , 2018, 132, 3036-3036.	0.6	0
46	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. <i>Blood</i> , 2018, 132, 3044-3044.	0.6	0
47	DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. <i>Blood</i> , 2017, 130, 753-762.	0.6	283
48	Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms. <i>Journal of Clinical Pathology</i> , 2016, 69, 1033-1036.	1.0	12